BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.

In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.

Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.